Kheng Hoe Kwa

Learn More
BACKGROUND AND OBJECTIVE Roflumilast, an oral, selective phosphodiesterase 4 inhibitor, has been shown to reduce exacerbations and improve pulmonary function in patients with COPD. This study examined the efficacy, safety and tolerability of roflumilast in Asian patients with COPD. METHODS Patients with COPD were randomized 1:1 to enter a 12-week(More)
  • 1